Prophylactic Human Vaccines: Market Research Report

January 2016 | 358 pages | ID: PD857ACD826EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Prophylactic Human Vaccines in US$ Million by the following Product Segments: Pediatric Prophylactic Vaccines, and Adult Prophylactic Vaccines.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.

Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 63 companies including many key and niche players such as -

• ALK Abelló A/S
• Altimmune, Inc.
• Bavarian Nordic A/S
• BiondVax Pharmaceuticals Ltd.
• Bharat Biotech International Limited

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Prophylactic Vaccines

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW & OUTLOOK

Human Vaccines: A Prelude
Human Vaccines Market – A Snapshot
Market Dynamics
Growth Drivers in a Capsule
Developed World: The Key Markets
Emerging Markets: The Future Growth Area
Vaccine Pricing: The Developed – Developing Divide

2. MARKET TRENDS & ISSUES

Prophylactic Pediatric Vaccines – A Mature Market
Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers
Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective Vaccines
Novel Vaccines against Emerging Infectious Diseases
Ongoing Developments for a Vaccine against Zika Virus
Sanofi’s Dengue Vaccine First-to-Market
Pipeline & Marketed Dengue Vaccine: 2016
Computational Tools Come to Aid in Development of Ebola Vaccines
Vaccine for AIDS
Ongoing Research for HIV Vaccine & Commercial Pipeline
List of Clinical Trial (Phase II) AIDS Vaccines: 2015
Staggering Global Statistics of AIDS – Opportunity Indicator

Table 1. HIV Infection Statistics Worldwide: As of 2014 (includes corresponding Graph/Chart)

Table 2. Worldwide HIV Prevalence and Incidence (in Million) by Region: 2014 (includes corresponding Graph/Chart)

Table 3. Worldwide AIDS related Deaths by Geographic Region: 2014 (includes corresponding Graph/Chart)

Table 4. HIV-Positive Individuals, by Gender (2014): Percentage Breakdown of Women and Men Tested HIV-Positive in all WHO Regions (includes corresponding Graph/Chart)

Vaccination-Autism Link and Other Safety Concerns Thwarted
Threat of Pandemic Rejuvenates Vaccine Market
Influenza Vaccines on a Growing Spree
Influenza Vaccines on the Current Market: 2016
H1N1 Vaccines Hit the Market in August 2009
H1N1 Influenza Vaccines and Manufacturers
Influenza Market Faces Several Challenges
Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market
Unmet Demand for TB Vaccine
Key TB Vaccine Candidates in the Pipeline: 2016
Need for a Human Vaccine for Leishmaniasis
Economic Factors Hamper Optimal Vaccine Development and Delivery
Increasing Need for Vaccine Promotion in the Developing Regions
Changing Vaccine Needs
Religious Concerns over Immunizing Young Girls against Human Papillomavirus
Changing Travel Patterns Increase Demand for Hepatitis B Vaccine
DNA Vaccines: Engineering Growth
Noninjectable Vaccines: Gain without Pain
Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines
Conjugate Vaccines: A Technological Innovation
Hib Vaccines on the Market: 2016
Growing Pricing Pressure – A Major Market Deterrent
Safety Issues Come to the Fore
BioWarfare: Threat Perception and Preparedness
Overview of Potential Bio-Terrorist Agents
Smallpox (Variola Major)
Anthrax (Bacillus Anthracis)
Plague (Yersinia Pestis)
Botulism (Clostridium Botulinum)
Tularemia (Francisella Tularensis)
Tackling Cold Chain Issues
Trade Statistics

Table 5. Global Exports of Human Vaccines by Leading Country (2013, 2014 & 2015): Percentage Share Breakdown of Export Value for Leading Exporters (includes corresponding Graph/Chart)

Table 6. Global Imports of Human Vaccines by Leading Country (2013, 2014 & 2015): Percentage Share Breakdown of Import Value for Leading Importers (includes corresponding Graph/Chart)

3. COMPETITIVE LANDSCAPE

Competitive Scenario
Leading Players

Table 7. Leading Players in the Global Human Vaccines Market (2015): Annual Sales in US$ Million for GlaxoSmithKline, Merck, Pfizer and Sanofi (includes corresponding Graph/Chart)

Table 8. Top Five Human Vaccines Worldwide by Sales Value: 2015 (In US$ Million) (includes corresponding Graph/Chart)

Pfizer Scores Big with Prevnar
Trumenba Shows Promise in Phase III Clinical Trials
GSK Takes Big Leap into the Meningococcal Vaccine Market
Acquired Products Strengthen GSK’s Vaccines Sales
The Potential for MenABCWY Vaccine

Table 9. US Meningococcal Disease Incidence by Serogroup Distribution (1990 & 2013): Percentage Breakdown of Disease Incidence for Serotypes B, C, Y and Others (includes corresponding Graph/Chart)

Sanofi Works on Production Issues to Boost Sales
New Vaccines to Enhance Prospects for Sanofi
Sanofi’s Human Vaccine R&D Pipeline
Weaker Sales Drive Merck and Sanofi’s European JV Split
Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market

4. PRODUCT OVERVIEW

Introduction to the Concept of Immunity
Role of Vaccines in Strengthening the Immune System
Vaccines and Immunotherapy
Historical Overview of Vaccines
How it Began
So Far So Good
Successful Vaccine Introductions in the Past
Contribution of Animal Research to Vaccine Production
Types of Vaccines
Live, Attenuated Vaccines
Combination Vaccines
Killed or Inactivated Vaccines
DNA & Recombinant DNA Vaccines
Toxoids
Cellular Fractions
Conjugate Vaccines
Subunit Vaccines
Passive Immunization
Prophylactic Vaccines
Prevention Better than Cure
Prophylactic Pediatric Vaccines
Vaccination over the Years
BCG Vaccine
Growth Boosting Factors for TB Vaccines
Demand Restraining Factors for TB Vaccines
Major Issues to be addressed in the TB Vaccine Market
Hemophilus Influenza Type B Vaccine
Diphtheria/Tetanus/Pertussis Vaccines
Hepatitis A Vaccine
Hepatitis B Vaccine
Hepatitis B Epidemiology
Measles/Mumps/Rubella Vaccines
Rotavirus Vaccines
Polio Vaccines
Varicella Vaccine
Combination Vaccines
Prophylactic Adult Vaccines
Hepatitis A Vaccine
Hepatitis B Vaccines
Key Issues Affecting the Adult Hepatitis Vaccines Market
Cholera Vaccine
Japanese Encephalitis Vaccines
Influenza Vaccines
Influenza A Virus
Influenza A (H1N1) Virus
Vaccine Virus Selection for the 2015-2016 Influenza Season
WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Northern Hemisphere for 2015-2016
WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Southern Hemisphere for 2015-2016
Lyme Disease Vaccine
Pneumococcal Disease Vaccines
Meningococcal Vaccines
Rabies Vaccines
Typhoid Vaccine
Yellow Fever Vaccine
Mechanisms for Vaccine Delivery
Edible Vaccines
Oral Vaccines
Tablet Based Vaccines
Mucosal Delivery
Transdermal Patch Delivery
Storage Problems
Perfluorocarbons as Alternative to Overcome Storage Problems
Costs
Standards for Vaccine Safety and Quality

5. CLINICAL TRIALS IN THE VACCINES MARKET

Inovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA Vaccine
Takeda Begins Phase2b Trial for World’s First Norovirus Vaccine
Bavarian Nordic Announces Positive Results from Phase 1 Trial of RSV Vaccine
Investigational Vaccine for P. vivax Malaria Enters Human Trials
Valneva Reports Postive Phase 2 Results for Vaccine Candidate against C. difficile
Novavax Announces Positive Phase 2 Clinical Trial Results for RSV-F Protein Vaccine
Vical Reports Postive Preclinical Data for CyMVectin CMV vaccine
Profectus BioSciences Receives HHS Contract to Accelerate Ebola Vaccine Candidate into Clinical Studies
Inovio and GeneOne to Advance Ebola Vaccine into Phase 1 Trial

6. PRODUCT LAUNCHES/APPROVALS

FDA Approves 2016/17 Formulation of Protein Sciences Corporation’s Flublok
Sanofi’s Dengue Vaccine Approved in Costa Rica
GSK Supplies Flu Vaccines based on Valneva’s EB66 Cell Line
FDA Approves Seqirus’ FLUCELVAX QUADRIVALENT Influenza Vaccine
China Launches HFMD Vaccine
Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection
Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection
WHO Accepts Merck’s Investigational Ebola Vaccine Application for Review
Sanofi’s Dengvaxia Receives Marketing Authorization in Mexico
SK Chemicals Launches Influenza Vaccine SKYCellflu
Sanofi Pasteur Ships First Doses of Fluzone for the US Market
Bharat Biotech Launches Made-in-India ROTAVAC Vaccine
FDA Approves Sanofi’s sBLA for Fluzone Vaccine
FDA Approves Merck’s HPV Vaccine GARDASIL9
Sanofi Pasteur Launches Shan5 Vaccine Developed by its Affiliate Shantha
US FDA Approves First Meningococcal Disease Vaccine Trumenba

7. RECENT INDUSTRY ACTIVITY

WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer’s Prevnar
Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics’ Facility
Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government
Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines
WHO Recommends Sanofi’s Dengvaxia in Nations with Widespread Dengue
Kaketsuken to Sell Vaccines Business to Astellas
Sanofi and Merck End Joint Venture on Vaccines
GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine
Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA
Bavarian Nordic Enters into License Agreement with Janssen
CSL Rebrands Influenza Vaccines Business as Seqirus
MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D
GlaxoSmithKline Acquires Novartis’ Vaccines Business
Vaxin Changes Name to Altimmune
Takeda Expands Commercialization Agreement with Nanotherapeutics
MedImmune Enters Into License Agreement with Inovio Pharmaceuticals
CSL Completes Acquisition of Novartis’ Influenza Vaccines Business
Pfizer to Acquire Meningitis Vaccines from GSK
Pfizer Stops Prevnar Vaccine Sales in China After Government Fails to Renew License
Takeda Transfers HPV Vaccine License Agreement to Kaketsuken
GlaxoSmithKline Acquires GlycoVaxyn
Pfizer Acquires Redvax GmbH
Pfizer Acquires Baxter’s Vaccines and Portion of Manufacturing Facility

8. FOCUS ON SELECT PLAYERS

ALK – Abello A/S (Denmark)
Altimmune, Inc. (US)
Bavarian Nordic A/S (Denmark)
BiondVax Pharmaceuticals Ltd. (Israel)
Bharat Biotech International Limited (India)
GlaxoSmithKline Plc. (UK)
Hualan Biological Engineering Inc. (China)
Janssen Pharmaceuticals, Inc. (US)
MedImmune (US)
Merck & Co., Inc. (US)
Pfizer Inc. (US)
Sanofi Pasteur SA (France)
Serum Institute of India Pvt. Ltd. (India)
Shanghai BravoBio Co., Ltd. (China)
Seqirus (UK)
SK Chemicals Co., Ltd. (Korea)
Takeda Pharmaceutical Company Limited (Japan)
Zydus Cadila (India)

9. GLOBAL MARKET PERSPECTIVE

Table 10. World Recent Past, Current & Future Analysis for Prophylactic Human Vaccines Prophylactic by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 11. World Historic Review for Prophylactic Human Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 12. World 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

Table 13. World Recent Past, Current & Future Analysis for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 14. World Historic Review for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 15. World 14-Year Perspective for Pediatric Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

Table 16. World Recent Past, Current & Future Analysis for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 17. World Historic Review for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 18. World 14-Year Perspective for Adult Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
Outlook
Key Growth Drivers
Select Market Constraints
Major Trends in the US Vaccines Development
Increasing Consolidation Activity among Companies
Combination Vaccines and New Delivery Models Gaining Traction
Protests against Vaccination Make Companies More Cautious
Technological Challenges in the Development of RSV Vaccines
Pediatric Vaccines Market
Improved Pricing Scenario for Pediatric Vaccines
Market Focus Shifting from Pediatric Vaccines
Growth Drivers for US Pediatric Vaccines Market
Demand Restraining Factors for US Pediatric Vaccines Market
Opportunity Indicators

Table 19. Number of Reported Cases for Vaccine-Preventable Diseases in American Regions: 2009-2013

Table 20. Routine Immunization Coverage in the US (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

The US Influenza Vaccine Market
‘Swine Flu’ Strain Returns in the 2013-14 Season

Table 21. CDC Price List for Pediatric Influenza Vaccines in Basic Package: 2015-2016

Table 22. CDC Price List for Adult Influenza Vaccines in Basic Package: 2015-2016

A Background on the Need for Flu Vaccines
Need for Immunization Schedule for Adults
Vaccines and Intended User Group
Adult Population: To Drive Future Growth of Pertussis Vaccines Market

Table 23. Pertussis Cases (In Thousands) for Years 2000 through 2014 (includes corresponding Graph/Chart)

Vaccine Pricing in the US
Regulatory Environment
Review Process Make Vaccines Safer
Imports-Exports Scenario

Table 24. US Exports of Human Vaccines by Country (2014 & 2015) - Percentage Breakdown of Export Value for Leading Destinations (includes corresponding Graph/Chart)

Table 25. US Imports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart)

Clinical Trials
Product Launches
Strategic Corporate Developments
Select Players
B. Market Analytics

Table 26. US Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 27. US Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 28. US 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

2. CANADA

A. Market Analysis
Outlook
Opposition to CMA’s Mandatory Vaccination Program

2009 H1N1 PANDEMIC BOOSTS VACCINES SALES

Trade Statistics

Table 29. Canadian Exports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Export Value for Leading Destinations (includes corresponding Graph/Chart)

Table 30. Canadian Imports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart)

B. Market Analytics

Table 31. Canadian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 32. Canadian Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 33. Canadian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

3. JAPAN

A. Market Analysis
Outlook
Controversy, Confusion and Hasty Actions Marr HPV Vaccination Market
Strategic Corporate Developments
Key Japan-based Player – Takeda Pharmaceutical Company Limited
B. Market Analytics

Table 34. Japanese Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 35. Japanese Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 36. Japanese 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis
Outlook
Vaccine Pricing in Europe
Major Drawbacks
Regulatory Mechanism for Vaccines in Europe
An Insight into European Influenza Vaccination Scenario
H3N2 Viruses Predominate in the 2014/15 Season; H1N1 Still in Circulation
Cell-based Vaccine Production Remains Nascent, Egg-based widely used
EU Welcomes Quadrivalent LAIVs
Major Influenza Vaccines Available in European Union Member Countries
Major H1N1 Flu Vaccines Available in Select East European Markets
B. Market Analytics

Table 37. European Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 38. European Historic Review for Prophylactic Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 39. European 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

Table 40. European Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 41. European Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 42. European 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4A. FRANCE

A. Market Analysis
Outlook
Clinical Trial
Product Launches
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 43. French Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 44. French Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 45. French 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4B. GERMANY

Market Analysis

Table 46. German Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 47. German Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 48. German 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4C. ITALY

Market Analysis

Table 49. Italian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 50. Italian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 51. Italian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4D. THE UNITED KINGDOM

A. Market Analysis
Outlook
Product Launch
Strategic Corporate Developments
Select Players
B. Market Analytics

Table 52. UK Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 53. UK Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 54. UK 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4E. SPAIN

Market Analysis

Table 55. Spanish Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 56. Spanish Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 57. Spanish 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4F. RUSSIA

Market Analysis

Table 58. Russian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 59. Russian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 60. Russian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4G. REST OF EUROPE

A. Market Analysis
Outlook
Clinical Trial
Strategic Corporate Developments
Select Players
B. Market Analytics

Table 61. Rest of Europe Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 62. Rest of Europe Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 63. Rest of Europe 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Outlook
Asian Vaccine Industry
Challenges

2014-15: DEADLIEST SWINE FLU SEASON IN INDIA SINCE 2009

Leading Influenza H1N1 Vaccine Brands Available in Select Asia-Pacific Markets
B. Market Analytics

Table 64. Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 65. Asia-Pacific Historic Review for Prophylactic Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 66. Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

Table 67. Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 68. Asia-Pacific Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 69. Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5A. CHINA

A. Market Analysis
Outlook
Large Population Offers High Potential
Growth Drivers
China – A Lucrative yet Difficult to Permeate Market
Product Launch
Strategic Corporate Development
Key Players
B. Market Analytics

Table 70. Chinese Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 71. Chinese Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 72. Chinese 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5B. INDIA

A. Market Analysis
Current & Future Analysis
Market Overview
Hepatitis B Vaccine in India
Combination Vaccines
Indian Vaccine Market – Select Combination Vaccines Available in the Country
The Patent Act (Third Amendment), 2005
Product Launches
Strategic Corporate Development
Select Players
B. Market Analytics

Table 73. Indian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 74. Indian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 75. Indian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/ Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5C. REST OF ASIA-PACIFIC

A. Market Analysis
Outlook
Malaysia – Stricken by Vaccine Shortage
Product Launches
Strategic Corporate Developments
Key Korea-based Player – SK Chemicals Co., Ltd.
B. Market Analytics

Table 76. Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 77. Rest of Asia-Pacific Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 78. Rest of Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

6. LATIN AMERICA

Market Analysis

Table 79. Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 80. Latin American Historic Review for Prophylactic Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 81. Latin American 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for Brazil, and Rest of Latin American Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

Table 82. Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 83. Latin American Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 84. Latin American 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

6A. BRAZIL

Market Analysis

Table 85. Brazilian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 86. Brazilian Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 87. Brazilian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

6B. REST OF LATIN AMERICA

A. Market Analysis
Outlook
Product Launches
B. Market Analytics

Table 88. Rest of Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 89. Rest of Latin American Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 90. Rest of Latin American 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

7. REST OF WORLD

A. Market Analysis
Outlook
Nigeria: A Severely Underserved Market

Table 91. Deaths in Nigerian Children Under Five Years by Cause (2015): Percentage Breakdown of Number of Deaths due to Diarrhoea, Malaria, Measles, Neonatal, Pneumonia, and Others (includes corresponding Graph/Chart)

BiondVax Pharmaceuticals Ltd. – A Key Israel-based Player
B. Market Analytics

Table 92. Rest of World Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 93. Rest of World Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 94. Rest of World 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 63 (including Divisions/Subsidiaries - 72)
The United States (22)
Canada (1)
Japan (5)
Europe (14)
  France (3)
  Germany (2)
  The United Kingdom (2)
  Spain (1)
  Rest of Europe (6)
Asia-Pacific (Excluding Japan) (28)
Latin America (1)
Middle East (1)